We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+6.51%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$341M
Cap. Flow
+$316M
Cap. Flow %
34.95%
Top 10 Hldgs %
51.85%
Holding
63
New
24
Increased
11
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$48.9M
2
UTHR icon
United Therapeutics
UTHR
+$25.4M
3
BIIB icon
Biogen
BIIB
+$24.9M
4
ARVN icon
Arvinas
ARVN
+$24.3M
5
JBIO
Jade Biosciences
JBIO
+$19.9M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$35.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$27.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$21.8M
4
BNTX icon
BioNTech
BNTX
+$18.2M
5
ETNB
89bio
ETNB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
26
CALL
Janux Therapeutics
JANX
$950M
$11.6M 1.28%
+500,000
New +$13.2M
ARVN icon
27
CALL
Arvinas
ARVN
$530M
$11M 1.22%
+1,500,000
New +$11M
BHVN icon
28
Biohaven
BHVN
$2.18B
$9.88M 1.09%
+700,000
New +$12.5M
XNCR icon
29
Xencor
XNCR
$1.47B
$9.82M 1.09%
+1,250,000
New +$11.2M
PRAX icon
30
Praxis Precision Medicines
PRAX
$8.8B
$9.46M 1.05%
+225,000
New +$8.57M
MLTX icon
31
MoonLake Immunotherapeutics
MLTX
$1.66B
$9.44M 1.04%
200,000
-150,000
-43% -$6.11M
CDTX
32
DELISTED
Cidara Therapeutics
CDTX
$9.25M 1.02%
+190,000
New +$4.57M
CBIO
33
Crescent Biopharma
CBIO
$626M
$8.94M 0.99%
553,686
+499,686
+925% +$10.6M
LEGN icon
34
Legend Biotech
LEGN
$3.73B
$8.87M 0.98%
+250,000
New +$8.1M
RYTM icon
35
Rhythm Pharmaceuticals
RYTM
$7.28B
$8.21M 0.91%
+130,000
New +$7.96M
MAZE
36
Maze Therapeutics
MAZE
$1.59B
$7.51M 0.83%
611,914
-325,000
-35% -$3.38M
LRMR icon
37
CALL
Larimar Therapeutics
LRMR
$398M
$7.22M 0.8%
+2,500,000
New +$5.79M
ELVN icon
38
Enliven Therapeutics
ELVN
$3.77B
$7.02M 0.78%
350,000
+110,000
+46% +$2.08M
JBIO
39
Jade Biosciences
JBIO
$1.21B
$6.24M 0.69%
625,000
+585,000
+1,463% +$19.9M
ANNX icon
40
Annexon
ANNX
$841M
$5.78M 0.64%
2,410,000
-1,590,000
-40% -$3.19M
MTSR
41
DELISTED
Metsera Inc
MTSR
$5.69M 0.63%
+200,000
New +$4.97M
TRVI icon
42
Trevi Therapeutics
TRVI
$2.57B
$4.65M 0.51%
850,000
+425,285
+100% +$2.65M
IMVT icon
43
Immunovant
IMVT
$8.23B
$4.4M 0.49%
275,000
– –
VSTM icon
44
Verastem
VSTM
$534M
$4.15M 0.46%
+1,000,000
New +$6.26M
ATXS
45
DELISTED
Astria Therapeutics
ATXS
$3.75M 0.42%
700,000
+200,000
+40% +$969K
BCAX
46
Bicara Therapeutics
BCAX
$1.83B
$3.72M 0.41%
+400,000
New +$4.77M
ACRS icon
47
Aclaris Therapeutics
ACRS
$750M
$2.63M 0.29%
1,850,000
-372,222
-17% -$504K
RAPP
48
Rapport Therapeutics
RAPP
$2.01B
$2.38M 0.26%
208,910
– –
UNCY icon
49
Unicycive Therapeutics
UNCY
$141M
$2.26M 0.25%
473,562
-34,331
-7% -$212K
SEPN
50
Septerna Inc
SEPN
$1.51B
$1.15M 0.13%
109,202
-25,000
-19% -$206K
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2025 Portfolio in Review

As of Q2 2025, Logos Global Management held 63 positions worth $904M, up 61% from $563M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $316M of net new capital in Q2 2025, opening 24 new positions and adding to 11 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $17.1M trimmed.

  • Logos Global Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.
  • Logos Global Management added most to Jade Biosciences in Q2 2025, an estimated $19.9M increase.
  • Logos Global Management's biggest Q2 2025 reduction was Janux Therapeutics, cutting an estimated $17.1M.
  • Logos Global Management fully exited Nuvalent in Q2 2025, selling an estimated $35.5M.
  • Logos Global Management's ten largest holdings make up 52% of its $904M portfolio in Q2 2025.
  • Logos Global Management opened 24 new positions and closed 12 in Q2 2025.
  • Logos Global Management's portfolio value rose 61% quarter-over-quarter to $904M.

Based on Logos Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.